The global single-use bioprocessing market size was valued at USD 19.36 billion in the year 2021 and is expected to cross USD 79.47 billion by 2030, registering a CAGR of 16.6% during the period in focus. The rising use of single-use bioprocessing technology in the vast biopharmaceuticals industry over the years along with rising investments made toward the development of biologics like vaccines, recombinant proteins, monoclonal antibodies, and a number of others will continue to drive the business scope in the times to come. Moreover, the benefits associated with the use of the technology, such as considerable reduction in time and cost needed for operation and facility construction have boosted the implementation of single-use solutions in the bioprocessing sector.
Globally, companies are increasingly using single-use bioprocessing solutions to meet their growing demand for biopharmaceuticals. They supplement the overall process efficiency and save expenses linked with daunting tasks like sterilizing, cleaning, as well as maintaining steel-based bioreactor systems. As per BioPharm International, single-use bioprocessing infrastructure comprises of nearly 85% of pre-commercial biomanufacturing infrastructures. A number of new technologies like big data, automation, and machine learning, are being used to meet the surging demand for pharmaceutical goods across the world.
The advent of the COVID-19 pandemic has steered growth opportunities in the industry with leading biopharmaceutical companies expanding their COVID-19-related product portfolio by advancing their manufacturing facilities through the implementation of single-use bioprocessing equipment. There is a growing number of biopharmaceutical companies that are actively involved in the development and production of coronavirus vaccines. The process of manufacturing is largely based on single-use technologies since these systems are cost-effective, flexible, and lower the risk of cross-contamination.
To request a sample copy or view summary of this report, "please" click the link below:
Single-Use Bioprocessing Market Report Highlights
• Product-wise, simple and peripheral elements led the segment accounting for over 48.85% of the global revenue share in 2021. The growth is due to the rising prominence of bioprocessing operations in the manufacturing process
• Media bags and containers are gradually leading the product segment owing to the expanded use of single-use bags across biomanufacturing processes. Single-use bioprocessing systems provide major benefits like lower capital investment, lower operation expenses, and a considerably lower environmental footprint, thus driving its use as media bags and containers to be used in a number of sectors
• Based on workflow insights, upstream bioprocessing held the largest share of over 57.6% of the global revenue in 2021. The high share is attributed to constant developments in technologies for upstream bioprocessing. For instance, the development of an advanced upstream process can help reduce the total time taken for upstream bioprocessing operations and is likely to boost the segmental growth in the times to come
• Considering end-use, biopharmaceutical manufacturers dominated the segment accounting for the largest share of over 58.1% of the revenue in 2021. The high geriatric population along with the increase in chronic diseases globally has driven the need for effective and reliable medication thus encouraging growth in the biopharmaceutical sector. Contract services adopted by biopharma companies is slated to further drive the segment
• Regionally, North America has emerged as a key application belt of single-use bioprocessing systems holding over 33% of the total revenue in 2021. The presence of a strong pharmaceutical and healthcare industry in the region along with the presence of the Bio-process Systems Alliance (BPSA) in the region that aims at driving the adoption of single-use technologies will continue to drive the business scope
• In line with the above, Asia Pacific is set to emerge as a profitable region for single-use bioprocessing market players due to heavy investments being made in the regional biopharmaceutical sector to take the growing cases of chronic diseases such as cancer, cardiovascular disease, and diabetes
Single-Use Bioprocessing Market Report Segments
Single-use Bioprocessing Product Outlook (Revenue, USD Million, 2018 - 2030)
• Simple & Peripheral Elements
• Tubing, Filters, Connectors, & Transfer Systems
• Sampling Systems
• Probes & Sensors
• pH Sensor
• Oxygen Sensor
• Pressure Sensors
• Temperature Sensors
• Conductivity Sensors
• Flow Sensors
• Apparatus & Plants
• Upto 1000L
• Above 1000L to 2000L
• Above 2000L
• Mixing, Storage, & Filling Systems
• Filtration System
• Chromatography Systems
• Work Equipment
• Cell Culture System
Single-use Bioprocessing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
• Upstream Bioprocessing
• Downstream Bioprocessing
Single-use Bioprocessing End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Biopharmaceutical Manufacturers
• CMOs & CROs
• In-house Manufacturers
• Academic & Clinical Research Institutes
Single-use Bioprocessing Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
• Asia Pacific
• South Korea
• Latin America
• Middle East and Africa (MEA)
• South Africa
• Saudi Arabia
List of Key Players in Single-use Bioprocessing Market
• Sartorius AG
• Danaher Corp.
• Thermo Fisher Scientific, Inc.
• Merck KGaA
• Avantor, Inc.
• Eppendorf SE
• Corning Inc.
• Boehringer Ingelheim International GmbH
• Infors AG
• PBS Biotech, Inc.
• Entegris, Inc.
• Kuhner AG
• Meissner Filtration Products, Inc.
• Rentschler Biopharma SE